Liver Testing Through a New Investigative Tool
Function Matters
HepQuant: A minimally invasive assessment of chronic liver disease
New Investigative Tools to Evaluate the Liver
assessment of chronic liver disease
Novel technology for minimally invasive
Liver Function Tests: Breaking Through Conventional Thinking About Liver Health Testing
HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.
Upcoming Events
Greg Everson, MD, HepQuant’s Chief Executive Officer, will be presenting at the NASH Summit 2019, scheduled April 22-25, 2019 in Boston. Everson will be a key speaker during the Clinical Stream Segment entitled “Strategic Considerations for Phase 3 Clinical Trials,” on Tuesday, April 23rd.
Recently Attended
HepQuant’s Chief Business Development Officer Brad Everson and Chief Scientific Officer Dr. Steve Helmke recently attended the 3rd edition of the International Workshop on NASH Biomarkers in Washington, DC.
Highlights from the 2nd Annual NASH Summit – Boston | April 2018
Recently Presented
- HepQuant attended the AASLD Liver Meeting in San Francisco, Nov. 9 – 13th. The event is typically attended by more than 9,500 hepatologists and hepatology health professionals from across the nation and around the world. (More info.) The company presented 2 posters:
- “Defining and Monitoring Liver Disease in Chronic Hepatitis C: A Comparison of the Disease Severity Index (DSI) from the HepQuant SHUNT test with Ishak Fibrosis (IFS) from Liver Biopsy.” Everson GT, Helmke SM. Hepatology 2018;68:910A. Annotation: This study suggests that DSI may be more sensitive than IFS in measuring serial changes in disease in patients with chronic hepatitis C.
- “Defining Disease Severity and Measuring Progression in Primary Sclerosing Cholangitis (PSC): A Comparison of the Disease Severity Index (DSI) from the HepQuant SHUNT Test with Serum Alkaline Phosphatase (Alk Phos).” Helmke SM, Everson GT. Hepatology 2018;1087A. Annotation: This study suggests that DSI may be more sensitive than Alk Phos in measuring serial changes in disease in patients with PSC.
LATEST NEWS
- Feb. 20 – Hoffman Joins HepQuant as Clinical Lab Manager
- Feb. 14 – First Patient Enrolled in a Pivotal Trial of the HepQuant SHUNT Liver Diagnostic Test
- Nov. 15 – Sarah Downing Joins HepQuant as Senior Manager of Quality Affairs
- Nov. 9 – Receives IDE Approval from U.S. FDA to Initiate Clinical Trial of the SHUNT Liver Diagnostic Kit
CONTACT US
These links are for informational purposes only and do not imply that HepQuant has any formal relationships with the organizations, nor do the organizations endorse HepQuant or its liver function tests.